Adma Biologics Well Placed For Launch In Supply: constrained market - analyst
12/08/2019 17:25
** Brokerage Oppenheimer sees favorable conditions ahead of
ADMA Biologics ADMA.O upcoming launch of its treatment Bivigam
for people with immune disorders after a WSJ report on Saturday
flagged shortage of immune globulin products
** Shares of drug developer ADMA up 4.9% at $3.65
** The shortage has forced U.S. hospitals and infusion
clinics to suspend treatment for many patients, according to the
report (https://on.wsj.com/2YYJBhN)
** The article provides further evidence of the undersupply
that characterizes the present market, conditions that are
favorable for ADMA as it brings Bivigam into the market later
this month, Oppenheimer analyst Leland Gershell says
** Gershell rates stock at "outperform" with PT of $14
** All 8 brokerages covering stock rate it at "buy" or
higher; their median PT is $11.75
** Up to Friday's close, stock had risen 45.6% YTD
(Reporting by Tamara Mathias in Bengaluru)
((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208;))